JCI Insight (Mar 2022)

Ferret models of alpha-1 antitrypsin deficiency develop lung and liver disease

  • Nan He,
  • Xiaoming Liu,
  • Amber R. Vegter,
  • T. Idil A. Evans,
  • Jaimie S. Gray,
  • Junfeng Guo,
  • Shashanna R. Moll,
  • Lydia J. Guo,
  • Meihui Luo,
  • Ningxia Ma,
  • Xingshen Sun,
  • Bo Liang,
  • Ziying Yan,
  • Zehua Feng,
  • Lisi Qi,
  • Arnav S. Joshi,
  • Weam Shahin,
  • Yaling Yi,
  • Katherine N. Gibson-Corley,
  • Eric A. Hoffman,
  • Kai Wang,
  • Christian Mueller,
  • John F. Engelhardt,
  • Bradley H. Rosen

Journal volume & issue
Vol. 7, no. 5

Abstract

Read online

Alpha-1 antitrypsin deficiency (AATD) is the most common genetic cause and risk factor for chronic obstructive pulmonary disease, but the field lacks a large-animal model that allows for longitudinal assessment of pulmonary function. We hypothesized that ferrets would model human AATD-related lung and hepatic disease. AAT-knockout (AAT-KO) and PiZZ (E342K, the most common mutation in humans) ferrets were generated and compared with matched controls using custom-designed flexiVent modules to perform pulmonary function tests, quantitative computed tomography (QCT), bronchoalveolar lavage (BAL) proteomics, and alveolar morphometry. Complete loss of AAT (AAT-KO) led to increased pulmonary compliance and expiratory airflow limitation, consistent with obstructive lung disease. QCT and morphometry confirmed emphysema and airspace enlargement, respectively. Pathway analysis of BAL proteomics data revealed inflammatory lung disease and impaired cellular migration. The PiZ mutation resulted in altered AAT protein folding in the liver, hepatic injury, and reduced plasma concentrations of AAT, and PiZZ ferrets developed obstructive lung disease. In summary, AAT-KO and PiZZ ferrets model the progressive obstructive pulmonary disease seen in AAT-deficient patients and may serve as a platform for preclinical testing of therapeutics including gene therapy.

Keywords